market opportunity
The marketplace
The mAb biosimilars market shows a strong growth potential, due to government support and current and imminent patent expiry of blockbuster mAb biologics.
The global biosimilar market is predicted to grow from US$6B in 2017 to US$36B in 2021.
Regulatory conditions are favourable; approvals by EMA and FDA are on the rise:
Challenges
However, there are 2 major challenges in the mAb biosimilars market:
-
A price war will evolve as in the generics market
-
Biosimilars currently sell at 70% of originator’s price, not counting some exceptions
-
Originator can afford competition down to 50% of current pricing
-
Huge market opportunity to compete <50% of current pricing
-
-
Inconvenient access and limited market reach
-
mAbs are administered subcutaneously or intravenously
-
Cold chain required
-
Convenient and stable mAb delivery would be a game-changer
-
